Retraction to: A retraction on inter-battery factor analysis (Psychometrika, (1961), 26, 4, (451-452), 10.1111/bph.15097);Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity

British Journal of Pharmacology

Volumn 163, Issue 2, 2011, Pages 299-312

  Spagnuolo, R D ^a   Recalcati, S ^a   Tacchini, L ^a   Cairo, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

apoptosis; cardiotoxicity; chelation; hypoxia inducible factors; iron

Indexed keywords

DOXORUBICIN; HEME OXYGENASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PROTEIN MCL 1; RAZOXANE; SURVIVIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL LINE; CELL STRAIN H9C2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; ENZYME ACTIVITY; HEART MUSCLE CELL; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

EID: 79954501357     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.15097     Document Type: Erratum

References (76)

1. Bernuzzi F, Recalcati S, Alberghini A, Cairo G, (2009). Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: role for heme oxygenase-1 down-modulation. Chem Biol Interact 177: 12-20.
2. Bianchi L, Tacchini L, Cairo G, (1999). HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res 27: 4223-4227. (Pubitemid 29500256)
3. Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB, (2007). Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 7: 114-121. (Pubitemid 47339857)
4. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP, (2002). Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-3394. (Pubitemid 34651384)
5. Corna G, Santambrogio P, Minotti G, Cairo G, (2004). doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J Biol Chem 279: 13738-13745. (Pubitemid 38468903)
6. Craig RW, (2002). MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16: 444-454. (Pubitemid 34449724)
7. De Ponti C, Carini R, Alchera E, Nitti MP, Locati M, Albano E, et al,. (2007). Adenosine A2a receptor-mediated, normoxic induction of HIF-1 through PKC and PI-3K-dependent pathways in macrophages. J Leukoc Biol 82: 392-402. (Pubitemid 47230651)
8. Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, Fargion S, (2008). Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 172: 738-747. (Pubitemid 351354546)
9. Eckle T, Kohler D, Lehmann R, El Kasmi K, Eltzschig HK, (2008). Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118: 166-175.
10. Fang D, Bao Y, Li X, Liu F, Cai K, Gao J, et al,. (2010). Effects of iron deprivation on multidrug resistance of leukemic K562 cells. Chemotherapy 56: 9-16.
11. Fang Y, Sullivan R, Graham CH, (2007). Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. Exp Cell Res 313: 867-877. (Pubitemid 46273437)
12. Gammella E, Cairo G, Tacchini L, (2010). Adenosine A(2)A receptor but not HIF-1 mediates Tyrosine hydroxylase induction in hypoxic PC12 cells. J Neurosci Res 88: 2007-2016.
13. Gewirtz DA, (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741. (Pubitemid 29094544)
14. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, et al,. (1997). Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15: 1906-1915. (Pubitemid 27209520)
15. Glasgow JN, Qiu J, Rassin D, Grafe M, Wood T, Perez-Pol JR, (2001). Transcriptional regulation of the BCL-X gene by NF-kappaB is an element of hypoxic responses in the rat brain. Neurochem Res 26: 647-659. (Pubitemid 32756829)
16. Guha M, Altieri DC, (2009). Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 8: 2708-2710.
17. Harten SK, Ashcroft M, Maxwell PH, (2010). Prolyl hydroxylase domain inhibitors: a route to HIF activation and neuroprotection. Antioxid Redox Signal 12: 459-480.
18. Hasinoff BB, Herman EH, (2007). Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc Toxicol 7: 140-144. (Pubitemid 47339861)
19. Hasinoff BB, Patel D, (2009). The iron chelator Dp44mT does not protect myocytes against doxorubicin. J Inorg Biochem 103: 1093-1101.
20. Hasinoff BB, Schroeder PE, Patel D, (2003). The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol Pharmacol 64: 670-678. (Pubitemid 37048570)
21. Hershko C, Link G, Tzahor M, Kaltwasser JP, Athias P, Grynberg A, et al,. (1993). Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J Lab Clin Med 122: 245-251.
22. Higgins DF, Kimura K, Iwano M, Haase VH, (2008). Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle 7: 1128-1132. (Pubitemid 351749261)
23. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, et al,. (1990). doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 87: 4275-4279.
24. Jones DT, Trowbridge IS, Harris AL, (2006). Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate. Cancer Res 66: 2749-2756.
25. Kaelin WG Jr, (2008). The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873.
26. Kaelin WG Jr, Ratcliffe PJ, (2008). Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402. (Pubitemid 351681994)
27. Kim HP, Ryter SW, Choi AM, (2006). CO as a cellular signaling molecule. Annu Rev Pharmacol Toxicol 46: 411-449. (Pubitemid 43271196)
28. Knowles HJ, Mole DR, Ratcliffe PJ, Harris AL, (2006). Normoxic stabilization of hypoxia-inducible factor-1alpha by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural resistance-associated macrophage protein 1. Cancer Res 66: 2600-2607.
29. Kobayashi S, Volden P, Timm D, Mao K, Xu X, Liang Q, (2010). Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J Biol Chem 285: 793-804.
30. Konorev EA, Vanamala S, Kalyanaraman B, (2008). Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes. Free Radical Biol Med 45: 1723-1728.
31. L'Ecuyer T, Allebban Z, Thomas R, Vander Heide R, (2004). Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am J Physiol 286: H2057-H2064. (Pubitemid 38685217)
32. Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, Kelly KM, (2004). Antioxidants and cancer therapy: a systematic review. J Clin Oncol 22: 517-528. (Pubitemid 41079781)
33. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL, (2009). Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 106: 2353-2358.
34. Levkau B, Schafers M, Wohlschlaeger J, Lipinski K, Keul P, Hermann S, et al,. (2008). Survivin determines cardiac function by controlling total cardiomyocyte number. Circulation 117: 1583-1593. (Pubitemid 351440646)
35. Li K, Sung RY, Huang WZ, Yang M, Pong NH, Lee SM, et al,. (2006). Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 113: 2211-2220.
36. Link G, Tirosh R, Pinson A, Hershko C, (1996). Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 127: 272-278. (Pubitemid 126657307)
37. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, et al,. (2010). Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11: 950-961.
38. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al,. (2007). Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67: 8839-8846. (Pubitemid 47437460)
39. Minotti G, Cairo G, Monti E, (1999). Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J 13: 199-212. (Pubitemid 29072398)
40. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004a). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229. (Pubitemid 38720829)
41. Minotti G, Recalcati S, Menna P, Salvatorelli E, Corna G, Cairo G, (2004b). Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol 378: 340-361.
42. Miranda CJ, Makui H, Soares RJ, Bilodeau M, Mui J, Vali H, et al,. (2003). Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. Blood 102: 2574-2580. (Pubitemid 37193598)
43. Mole DR, (2010). Iron homeostasis and its interaction with prolyl hydroxylases. Antioxid Redox Signal 12: 445-458.
44. Mukhopadhyay P, Batkai S, Rajesh M, Czifra N, Harvey-White J, Hasko G, et al,. (2007). Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 50: 528-536. (Pubitemid 47126779)
45. Nagel S, Talbot NP, Mecinovic J, Smith TG, Buchan AM, Schofield CJ, (2010). Therapeutic manipulation of the HIF hydroxylases. Antioxid Redox Signal 12: 481-501.
46. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, et al,. (2007). Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 117: 1926-1932. (Pubitemid 47036326)
47. Peyssonnaux C, Nizet V, Johnson RS, (2008). Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle 7: 28-32.
48. Popelova O, Sterba M, Simunek T, Mazurova Y, Guncova I, Hroch M, et al,. (2008). Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. J Pharmacol Exp Ther 326: 259-269. (Pubitemid 351872152)
49. Popelova O, Sterba M, Haskova P, Simunek T, Hroch M, Guncova I, et al,. (2009). Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br J Cancer 101: 792-802.
50. Recalcati S, Minotti G, Cairo G, (2010). Iron regulatory proteins: from molecular mechanisms to drug development. Antioxid Redox Signal 13: 1593-1616.
51. Reeve JL, Szegezdi E, Logue SE, Chonghaile TN, O'Brien T, Ritter T, et al,. (2007). Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-xL. J Cell Mol Med 11: 509-520. (Pubitemid 47153461)
52. Riganti C, Doublier S, Aldieri E, Orecchia S, Betta PG, Gazzano E, et al,. (2008). Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha. Eur Respir J 32: 443-451.
53. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA, (1999). Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 84: 257-265. (Pubitemid 29095566)
54. Schofield CJ, Ratcliffe PJ, (2004). Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5: 343-354. (Pubitemid 38579472)
55. Scortegagna M, Ding K, Oktay Y, Gaur A, Thurmond F, Yan LJ, et al,. (2003). Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat Genet 35: 331-340. (Pubitemid 37486916)
56. Semenza GL, (2009). Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology 24: 97-106.
57. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, et al,. (1996). Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529-32537.
58. Shi R, Huang CC, Aronstam RS, Ercal N, Martin A, Huang YW, (2009). N-acetylcysteine amide decreases oxidative stress but not cell death induced by doxorubicin in H9c2 cardiomyocytes. BMC Pharmacol 9: 7.
59. Shroff EH, Snyder C, Chandel NS, (2007). Bcl-2 family members regulate anoxia-induced cell death. Antioxid Redox Signal 9: 1405-1409. (Pubitemid 47255020)
60. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V, (2009). Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61: 154-171.
61. Singal PK, Iliskovic N, (1998). doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905. (Pubitemid 28446849)
62. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, et al,. (2004). Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37: 837-846. (Pubitemid 39222076)
63. Sterba M, Popelova O, Simunek T, Mazurova Y, Potacova A, Adamcova M, et al,. (2006). Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. J Pharmacol Exp Ther 319: 1336-1347.
64. Tacchini L, Matteucci E, De Ponti C, Desiderio MA, (2003). Hepatocyte growth factor signaling regulates transactivation of genes belonging to the plasminogen activation system via hypoxia inducible factor-1. Exp Cell Res 290: 391-401. (Pubitemid 37272181)
65. Tacchini L, De Ponti C, Matteucci E, Follis R, Desiderio MA, (2004). Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis 25: 2089-2100. (Pubitemid 39534845)
66. Tacchini L, Gammella E, De Ponti C, Recalcati S, Cairo G, (2008). Role of HIF-1 and NF-kappaB transcription factors in the modulation of transferrin receptor by inflammatory and anti-inflammatory signals. J Biol Chem 283: 20674-20686.
67. Takara K, Sakaeda T, Okumura K, (2006). An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12: 273-286.
68. Thompson KL, Rosenzweig BA, Zhang J, Knapton AD, Honchel R, Lipshultz SE, et al,. (2010). Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Cancer Chemother Pharmacol 66: 303-314.
69. Turakhia S, Venkatakrishnan CD, Dunsmore K, Wong H, Kuppusamy P, Zweier JL, et al,. (2007). doxorubicin-induced cardiotoxicity: direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27. Am J Physiol 293: H3111-H3121. (Pubitemid 350106537)
70. Wang GL, Semenza GL, (1993). Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82: 3610-3615. (Pubitemid 24006041)
71. Weiss G, Kastner S, Brock J, Thaler J, Grunewald K, (1997). Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein. Biochem Pharmacol 53: 1419-1424. (Pubitemid 27356113)
72. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE, (2005). Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131: 561-578. (Pubitemid 43899624)
73. Xu X, Sutak R, Richardson DR, (2008). Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. Mol Pharmacol 73: 833-844. (Pubitemid 351397888)
74. Yamazaki Y, Hasebe Y, Egawa K, Nose K, Kunimoto S, Ikeda D, (2006). Anthracyclines, small-molecule inhibitors of hypoxia-inducible factor-1 alpha activation. Biol Pharm Bull 29: 1999-2003. (Pubitemid 44510798)
75. Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK, (1996). The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 98: 1253-1260. (Pubitemid 26299939)
76. Zhou L, Sung RY, Li K, Pong NH, Xiang P, Shen J, et al,. (2010). Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis. Int J Cardiol Aug 5. [Epub ahead of print].